{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:18:17Z","timestamp":1769602697820,"version":"3.49.0"},"reference-count":108,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,3,12]],"date-time":"2017-03-12T00:00:00Z","timestamp":1489276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,3,12]],"date-time":"2017-03-12T00:00:00Z","timestamp":1489276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1111\/ane.12758","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T15:14:35Z","timestamp":1489504475000},"page":"558-569","source":"Crossref","is-referenced-by-count":11,"title":["Causally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease"],"prefix":"10.1155","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-7305","authenticated-orcid":false,"given":"J.","family":"Finsterer","sequence":"first","affiliation":[{"name":"Krankenanstalt Rudolfstiftung; Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wanschitz","sequence":"additional","affiliation":[{"name":"Department of Neurology; Medical University Innsbruck; Innsbruck Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Quasthoff","sequence":"additional","affiliation":[{"name":"Department of Neurology; Medical University Graz; Graz Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Iglseder","sequence":"additional","affiliation":[{"name":"Neurological Department; KH Barmherzige Br\u00fcder; Linz Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"L\u00f6scher","sequence":"additional","affiliation":[{"name":"Department of Neurology; Medical University Innsbruck; Innsbruck Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Grisold","sequence":"additional","affiliation":[{"name":"Neurological Department; Kaiser-Franz Josef Spital; Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,12]]},"reference":[{"key":"10.1111\/ane.12758-BIB0001|ane12758-cit-0001","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/mus.23775","article-title":"Inherited neuropathies: clinical overview and update","volume":"48","author":"Klein","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12758-BIB0002|ane12758-cit-0002","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/ane.12758-BIB0003|ane12758-cit-0003","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.pediatrneurol.2010.02.006","article-title":"Acute progression of neuromuscular findings in infantile Pompe disease","volume":"42","author":"Burrow","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1111\/ane.12758-BIB0004|ane12758-cit-0004","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.clinph.2016.02.013","article-title":"The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy","volume":"127","author":"Castro","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"10.1111\/ane.12758-BIB0005|ane12758-cit-0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/2141-9248.183935","article-title":"Fabry's disease: case series and review of literature","volume":"6","author":"Wani","year":"2016","journal-title":"Ann Med Health Sci Res"},{"key":"10.1111\/ane.12758-BIB0006|ane12758-cit-0006","first-page":"40","article-title":"Morbus Fabry-Neurologische Klinik und M\u00f6glkichkeiten der Therapie","volume":"1","author":"Haas","year":"2004","journal-title":"J Neurol Neurochir Psychiatr"},{"key":"10.1111\/ane.12758-BIB0007|ane12758-cit-0007","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/bbrc.1999.0310","article-title":"Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches","volume":"257","author":"Germain","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/ane.12758-BIB0008|ane12758-cit-0008","volume-title":"Morbus Fabry. Klinische Manifestationen, Diagnostik und Therapie","author":"Beck","year":"2007"},{"key":"10.1111\/ane.12758-BIB0009|ane12758-cit-0009","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1111\/ane.12758-BIB0010|ane12758-cit-0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","article-title":"The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain","volume":"594","author":"Choi","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1111\/ane.12758-BIB0011|ane12758-cit-0011","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","article-title":"Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)","volume":"9","author":"Liu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/ane.12758-BIB0012|ane12758-cit-0012","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1529-8027.2012.00438.x","article-title":"Upregulation of inward rectifying currents and Fabry disease neuropathy","volume":"17","author":"Geevasinga","year":"2012","journal-title":"J Peripher Nerv Syst"},{"key":"10.1111\/ane.12758-BIB0013|ane12758-cit-0013","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pediatrneurol.2016.07.001","article-title":"Fabry disease: a disorder of childhood onset","volume":"64","author":"Schiffmann","year":"2016","journal-title":"Pediatr Neurol"},{"key":"10.1111\/ane.12758-BIB0014|ane12758-cit-0014","volume-title":"Fabry Disease: Perspectives from 5 Years of FOS","year":"2006"},{"key":"10.1111\/ane.12758-BIB0015|ane12758-cit-0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00482-012-1238-1","article-title":"Fabry disease: diagnosis and treatment","volume":"26","author":"\u00dc\u00e7eyler","year":"2012","journal-title":"Schmerz"},{"key":"10.1111\/ane.12758-BIB0016|ane12758-cit-0016","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/archneur.1974.00490380068009","article-title":"Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns","volume":"31","author":"Onishi","year":"1974","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12758-BIB0017|ane12758-cit-0017","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3988\/jcn.2014.10.2.108","article-title":"Idiopathic small fiber neuropathy: phenotype, etiologies, and the search for Fabry disease","volume":"10","author":"Samuelsson","year":"2014","journal-title":"J Clin Neurol"},{"key":"10.1111\/ane.12758-BIB0018|ane12758-cit-0018","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2377-10-38","article-title":"Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests","volume":"10","author":"Biegstraaten","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1111\/ane.12758-BIB0019|ane12758-cit-0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/8904_2011_37","article-title":"Carpal tunnel syndrome in Fabry disease","volume":"2","author":"Ghali","year":"2012","journal-title":"JIMD Rep"},{"key":"10.1111\/ane.12758-BIB0020|ane12758-cit-0020","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1756283X16642936","article-title":"Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis","volume":"9","author":"Zar-Kessler","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"issue":"suppl 2","key":"10.1111\/ane.12758-BIB0021|ane12758-cit-0021","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1097\/01.ASN.0000015239.57436.18","article-title":"Anderson-Fabry disease: extrarenal, neurologic manifestations","volume":"13","author":"Kolodny","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/ane.12758-BIB0022|ane12758-cit-0022","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00868342","article-title":"Stroke in Fabry's disease","volume":"241","author":"Grewal","year":"1994","journal-title":"J Neurol"},{"key":"10.1111\/ane.12758-BIB0023|ane12758-cit-0023","doi-asserted-by":"publisher","first-page":"e0143940","DOI":"10.1371\/journal.pone.0143940","article-title":"Positron emission tomography and magnetic resonance imaging of the brain in Fabry disease: a nationwide, long-time, prospective follow-up","volume":"10","author":"Korsholm","year":"2015","journal-title":"PLoS One"},{"key":"10.1111\/ane.12758-BIB0024|ane12758-cit-0024","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.50.6.1746","article-title":"Quantitative analysis of cerebral vasculopathy in patients with Fabry disease","volume":"50","author":"Crutchfield","year":"1998","journal-title":"Neurology"},{"key":"10.1111\/ane.12758-BIB0025|ane12758-cit-0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/NRL.0b013e3182761cf6","article-title":"Fabry disease with atypical neurological presentation: report of a case","volume":"18","author":"Simoncini","year":"2012","journal-title":"Neurologist"},{"key":"10.1111\/ane.12758-BIB0026|ane12758-cit-0026","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.0000000000001450","article-title":"Clinical prodromes of neurodegeneration in Anderson-Fabry disease","volume":"84","author":"L\u00f6hle","year":"2015","journal-title":"Neurology"},{"key":"10.1111\/ane.12758-BIB0027|ane12758-cit-0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/8904_2016_549","article-title":"Sleep disturbance, obstructive sleep apnoea and abnormal periodic leg movements: very common problems in Fabry disease","volume":"31","author":"Talbot","year":"2017","journal-title":"JIMD Rep"},{"key":"10.1111\/ane.12758-BIB0028|ane12758-cit-0028","first-page":"1","volume-title":"Fabry Disease: Review and New Perspectives","author":"Brady","year":"2001"},{"key":"10.1111\/ane.12758-BIB0029|ane12758-cit-0029","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2009.06.032","article-title":"Functional and structural nerve fiber findings in heterozygote patients with Fabry disease","volume":"145","author":"Torvin M\u00f8ller","year":"2009","journal-title":"Pain"},{"key":"10.1111\/ane.12758-BIB0030|ane12758-cit-0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s004150050125","article-title":"Nerve biopsy findings in hemizygous and heterozygous patients with Fabry's disease","volume":"244","author":"Toyooka","year":"1997","journal-title":"J Neurol"},{"key":"10.1111\/ane.12758-BIB0031|ane12758-cit-0031","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2377-13-47","article-title":"Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study","volume":"13","author":"\u00dc\u00e7eyler","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1111\/ane.12758-BIB0032|ane12758-cit-0032","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12542","article-title":"Pain in Fabry disease: practical recommendations for diagnosis and treatment","volume":"22","author":"Politei","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1111\/ane.12758-BIB0033|ane12758-cit-0033","first-page":"135","article-title":"Sudoscan as a noninvasive tool to assess sudomotor dysfunction in patients with Fabry disease: results from a case-control study","volume":"12","author":"Sahuc","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/ane.12758-BIB0034|ane12758-cit-0034","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/8904_2014_342","article-title":"Uncertain diagnosis of Fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up","volume":"17","author":"Tol","year":"2014","journal-title":"JIMD Rep"},{"key":"10.1111\/ane.12758-BIB0035|ane12758-cit-0035","doi-asserted-by":"publisher","first-page":"e0148316","DOI":"10.1371\/journal.pone.0148316","article-title":"No Fabry disease in patients presenting with isolated small fiber neuropathy","volume":"11","author":"Greef","year":"2016","journal-title":"PLoS One"},{"key":"10.1111\/ane.12758-BIB0036|ane12758-cit-0036","first-page":"1","article-title":"A novel mutation of \u03b1-galactosidase A gene causes Fabry disease mimicking primary erythromelalgia in a Chinese family","author":"Ge","year":"2016","journal-title":"Int J Neurosci"},{"key":"10.1111\/ane.12758-BIB0037|ane12758-cit-0037","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/14737175.2015.1013097","article-title":"Progress in the treatment of small fiber peripheral neuropathy","volume":"15","author":"Chiang","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1111\/ane.12758-BIB0038|ane12758-cit-0038","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-016-0549-8","article-title":"Pain management strategies for neuropathic pain in Fabry disease-a systematic review","volume":"16","author":"Schuller","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1111\/ane.12758-BIB0039|ane12758-cit-0039","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/00007890-199211000-00030","article-title":"Living kidney donor and recipient evaluation in Fabry's disease","volume":"54","author":"Schweitzer","year":"1992","journal-title":"Transplantation"},{"key":"10.1111\/ane.12758-BIB0040|ane12758-cit-0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/01913123.2010.538136","article-title":"Unexpected Fabry disease in a renal allograft kidney: an underrecognized cause of poor allograft function","volume":"35","author":"Kochar","year":"2011","journal-title":"Ultrastruct Pathol"},{"key":"10.1111\/ane.12758-BIB0041|ane12758-cit-0041","first-page":"1","article-title":"Female with Fabry disease unknowingly donates affected kidney to sister: a call for pre-transplant genetic testing","volume":"4","author":"Paull","year":"2012","journal-title":"JIMD Rep"},{"key":"10.1111\/ane.12758-BIB0042|ane12758-cit-0042","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1111\/ane.12758-BIB0043|ane12758-cit-0043","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/8904_2015_483","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Rep"},{"key":"10.1111\/ane.12758-BIB0044|ane12758-cit-0044","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-016-0473-4","article-title":"Multicenter Female Fabry Study (MFFS)-clinical survey on current treatment of females with Fabry disease","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/ane.12758-BIB0045|ane12758-cit-0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/8904_2015_422","article-title":"Effect and tolerability of agalsidase alfa in patients with fabry disease who were treatment na\u00efve or formerly treated with agalsidase beta or agalsidase alfa","volume":"23","author":"Goker-Alpan","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1111\/ane.12758-BIB0046|ane12758-cit-0046","doi-asserted-by":"publisher","first-page":"CD006663","DOI":"10.1002\/14651858.CD006663.pub4","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"El Dib","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12758-BIB0047|ane12758-cit-0047","doi-asserted-by":"publisher","first-page":"e010422","DOI":"10.1136\/bmjopen-2015-010422","article-title":"Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y","volume":"6","author":"Oder","year":"2016","journal-title":"BMJ Open"},{"key":"10.1111\/ane.12758-BIB0048|ane12758-cit-0048","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw334","article-title":"Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease","author":"Lenders","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ane.12758-BIB0049|ane12758-cit-0049","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10\u00a0years\u2019 treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/ane.12758-BIB0050|ane12758-cit-0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)","volume":"42","author":"Hoffmann","year":"2005","journal-title":"J Med Genet"},{"key":"10.1111\/ane.12758-BIB0051|ane12758-cit-0051","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1529-8027.2011.00365.x","article-title":"Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy","volume":"16","author":"\u00dc\u00e7eyler","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"10.1111\/ane.12758-BIB0052|ane12758-cit-0052","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet"},{"key":"10.1111\/ane.12758-BIB0053|ane12758-cit-0053","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ane.12758-BIB0054|ane12758-cit-0054","doi-asserted-by":"publisher","first-page":"282405","DOI":"10.1155\/2015\/282405","article-title":"Ocular manifestations and therapeutic options in patients with familial amyloid polyneuropathy: a systematic review","volume":"2015","author":"Martins","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1111\/ane.12758-BIB0055|ane12758-cit-0055","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1007\/s00018-009-0109-0","article-title":"Transthyretin: the servant of many masters","volume":"66","author":"Buxbaum","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1111\/ane.12758-BIB0056|ane12758-cit-0056","volume-title":"Heredit\u00e4re Amyloidneuropathien","author":"Sommer","year":"2016"},{"issue":"suppl 1","key":"10.1111\/ane.12758-BIB0057|ane12758-cit-0057","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1111\/ane.12758-BIB0058|ane12758-cit-0058","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/13506129.2015.1127223","article-title":"Transthyretin-related hereditary amyloid polyneuropathy presenting with large fibre involvement and cardiomyopathy","volume":"23","author":"Cruz","year":"2016","journal-title":"Amyloid"},{"issue":"suppl 1","key":"10.1111\/ane.12758-BIB0059|ane12758-cit-0059","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/13506129.2003.12088561","article-title":"Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration","volume":"10","author":"Said","year":"2003","journal-title":"Amyloid"},{"key":"10.1111\/ane.12758-BIB0060|ane12758-cit-0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/B978-0-444-52902-2.00038-2","article-title":"Transthyretin familial amyloid polyneuropathy","volume":"115","author":"Plant\u00e9-Bordeneuve","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1111\/ane.12758-BIB0061|ane12758-cit-0061","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","article-title":"Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)","volume":"69","author":"Plant\u00e9-Bordeneuve","year":"2007","journal-title":"Neurology"},{"key":"10.1111\/ane.12758-BIB0062|ane12758-cit-0062","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5692\/clinicalneurol.cn-000852","article-title":"A case of familial amyloid polyneuropathy (FAP ATTR Ile107Val) with proximal muscle weakness in the lower extremities","volume":"56","author":"Kuzume","year":"2016","journal-title":"Rinsho Shinkeigaku (Clin Neurol)"},{"key":"10.1111\/ane.12758-BIB0063|ane12758-cit-0063","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/openhrt-2015-000289","article-title":"Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy","volume":"3","author":"Damy","year":"2016","journal-title":"Open Heart"},{"key":"10.1111\/ane.12758-BIB0064|ane12758-cit-0064","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1212\/NXG.0000000000000018","article-title":"Tongue atrophy and fasciculations in transthyretin familial amyloid neuropathy: an ALS mimicker","volume":"1","author":"Goyal","year":"2015","journal-title":"Neurol Genet"},{"key":"10.1111\/ane.12758-BIB0065|ane12758-cit-0065","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/18.3.532","article-title":"Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy","volume":"18","author":"Lobato","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ane.12758-BIB0066|ane12758-cit-0066","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00415-012-6816-8","article-title":"Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers","volume":"260","author":"Lefaucheur","year":"2013","journal-title":"J Neurol"},{"key":"10.1111\/ane.12758-BIB0067|ane12758-cit-0067","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/DAD.0000000000000501","article-title":"Cutaneous manifestations of familial transthyretin amyloid polyneuropathy","volume":"38","author":"Lanoue","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"10.1111\/ane.12758-BIB0068|ane12758-cit-0068","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/14656566.2016.1145664","article-title":"TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies","volume":"17","author":"Adams","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/ane.12758-BIB0069|ane12758-cit-0069","first-page":"763","article-title":"Familial amyloid polyneuropathy: liver transplantation as first-line therapy","volume":"66","author":"Yamashita","year":"2014","journal-title":"Brain Nerve"},{"key":"10.1111\/ane.12758-BIB0070|ane12758-cit-0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1111\/ane.12758-BIB0071|ane12758-cit-0071","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-014-0260-2","article-title":"Tafamidis: a review of its use in familial amyloid polyneuropathy","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"10.1111\/ane.12758-BIB0072|ane12758-cit-0072","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13506120410001673884","article-title":"End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors","volume":"11","author":"Lobato","year":"2004","journal-title":"Amyloid"},{"key":"10.1111\/ane.12758-BIB0073|ane12758-cit-0073","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant'Anna","year":"2016","journal-title":"Nat Commun"},{"key":"10.1111\/ane.12758-BIB0074|ane12758-cit-0074","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/ane.12758-BIB0075|ane12758-cit-0075","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/ane.12758-BIB0076|ane12758-cit-0076","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/13506129.2015.1123149","article-title":"Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation","volume":"23","author":"Okumura","year":"2016","journal-title":"Amyloid"},{"key":"10.1111\/ane.12758-BIB0077|ane12758-cit-0077","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12758-BIB0078|ane12758-cit-0078","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1212\/WNL.0b013e318248df18","article-title":"Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy","volume":"78","author":"Yamashita","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/ane.12758-BIB0079|ane12758-cit-0079","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4322\/acr.2015.022","article-title":"The infantile-onset form of Pompe disease: an autopsy diagnosis","volume":"5","author":"Santos","year":"2015","journal-title":"Autops Case Rep"},{"key":"10.1111\/ane.12758-BIB0080|ane12758-cit-0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10545-015-9898-5","article-title":"Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy","volume":"39","author":"Broomfield","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/ane.12758-BIB0081|ane12758-cit-0081","doi-asserted-by":"publisher","DOI":"10.1007\/8904_2016_576","article-title":"Swallow prognosis and follow-up protocol in infantile onset Pompe disease","author":"Swift","year":"2016","journal-title":"JIMD Rep"},{"key":"10.1111\/ane.12758-BIB0082|ane12758-cit-0082","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13023-016-0446-7","article-title":"Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study","volume":"11","author":"Peng","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/ane.12758-BIB0083|ane12758-cit-0083","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"10.1111\/ane.12758-BIB0084|ane12758-cit-0084","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"10.1111\/ane.12758-BIB0085|ane12758-cit-0085","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.5664\/jcsm.6346","article-title":"Sleep-disordered breathing and effects of noninvasive ventilation in patients with late-onset Pompe disease","volume":"12","author":"Boentert","year":"2016","journal-title":"J Clin Sleep Med"},{"key":"10.1111\/ane.12758-BIB0086|ane12758-cit-0086","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13023-016-0480-5","article-title":"Analysis of voice quality in patients with late-onset Pompe disease","volume":"11","author":"Szklanny","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/ane.12758-BIB0087|ane12758-cit-0087","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymgmr.2016.06.002","article-title":"Hypothyroidism in late-onset Pompe disease","volume":"8","author":"Schneider","year":"2016","journal-title":"Mol Genet Metab Rep"},{"key":"10.1111\/ane.12758-BIB0088|ane12758-cit-0088","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/8904_2016_563","article-title":"Severe cardiomyopathy as the isolated presenting feature in an adult with late-onset Pompe disease: a case report","volume":"31","author":"Mori","year":"2017","journal-title":"JIMD Rep"},{"key":"10.1111\/ane.12758-BIB0089|ane12758-cit-0089","first-page":"50","article-title":"A 62-year-old man with dyspnea","volume":"17","author":"Baqir","year":"2016","journal-title":"Respir Med Case Rep"},{"key":"10.1111\/ane.12758-BIB0090|ane12758-cit-0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.12659\/AJCR.893309","article-title":"Small-fiber neuropathy in pompe disease: first reported cases and prospective screening of a clinic cohort","volume":"16","author":"Hobson-Webb","year":"2015","journal-title":"Am J Case Rep"},{"key":"10.1111\/ane.12758-BIB0091|ane12758-cit-0091","first-page":"82","article-title":"Diffuse cerebral microhemorrhages in a patient with adult-onset Pompe's disease: a case report","volume":"7","author":"Sandhu","year":"2014","journal-title":"J Vasc Interv Neurol"},{"key":"10.1111\/ane.12758-BIB0092|ane12758-cit-0092","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"M\u00fcller-Felber","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1111\/ane.12758-BIB0093|ane12758-cit-0093","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCGENETICS.115.001322","article-title":"Elevated plasma cardiac troponin T levels caused by skeletal muscle damage in Pompe disease","volume":"9","author":"Wens","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1111\/ane.12758-BIB0094|ane12758-cit-0094","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/mus.24620","article-title":"Electromyographic findings in 37 patients with adult-onset acid maltase deficiency","volume":"51","author":"Kassardjian","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12758-BIB0095|ane12758-cit-0095","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ymgmr.2015.03.010","article-title":"Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy","volume":"3","author":"Gruhn","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"10.1111\/ane.12758-BIB0096|ane12758-cit-0096","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1212\/WNL.0000000000002321","article-title":"Bright tongue sign in Pompe disease","volume":"86","author":"Karam","year":"2016","journal-title":"Neurology"},{"key":"10.1111\/ane.12758-BIB0097|ane12758-cit-0097","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.nmd.2015.04.008","article-title":"Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: a Spanish cohort","volume":"25","author":"Guti\u00e9rrez-Rivas","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1111\/ane.12758-BIB0098|ane12758-cit-0098","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-510X(81)90041-1","article-title":"Late-onset acid maltase deficiency. Biochemical studies of leukocytes","volume":"50","author":"Shanske","year":"1981","journal-title":"J Neurol Sci"},{"key":"10.1111\/ane.12758-BIB0099|ane12758-cit-0099","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","article-title":"Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial","volume":"15","author":"Klinge","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1111\/ane.12758-BIB0100|ane12758-cit-0100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1590\/0004-282X20150194","article-title":"Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease","volume":"74","author":"Llerena Junior","year":"2016","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1111\/ane.12758-BIB0101|ane12758-cit-0101","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.nmd.2016.02.016","article-title":"Multidisciplinary care allowing uneventful vaginal delivery in a woman with Pompe disease","volume":"26","author":"Perniconi","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1111\/ane.12758-BIB0102|ane12758-cit-0102","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/jog.13055","article-title":"Pregnancy and associated events in women receiving enzyme replacement therapy for late-onset glycogen storage disease type II (Pompe disease)","volume":"42","author":"Rohman","year":"2016","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1111\/ane.12758-BIB0103|ane12758-cit-0103","first-page":"269","article-title":"Clinical guidelines for infantile-onset Pompe disease","volume":"63","author":"Pascual-Pascual","year":"2016","journal-title":"Rev Neurol"},{"key":"10.1111\/ane.12758-BIB0104|ane12758-cit-0104","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J Pediatr"},{"key":"10.1111\/ane.12758-BIB0105|ane12758-cit-0105","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.nmd.2016.07.006","article-title":"SWORD: a simplified desensitization protocol for enzyme replacement therapy in adult Pompe disease","volume":"26","author":"Gallay","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1111\/ane.12758-BIB0106|ane12758-cit-0106","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12758-BIB0107|ane12758-cit-0107","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","article-title":"Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY Study","volume":"119","author":"Ploeg","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1111\/ane.12758-BIB0108|ane12758-cit-0108","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","article-title":"Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5 years","volume":"117","author":"Stepien","year":"2016","journal-title":"Mol Genet Metab"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12758\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:50:28Z","timestamp":1671540628000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,12]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12758","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3,12]]}}}